硫酸镁联合拉贝洛尔治疗妊娠期高血压疾病临床疗效分析

Clinical Analysis of Magnesium Sulfate Combined with Labetalol in Treating Hypertensive Disorder Complicating Pregnancy

目的探讨硫酸镁联合拉贝洛尔治疗妊娠期高血压疾病的临床疗效。方法该文以2016年5月—2017年5月该院治疗的妊娠期高血压患者96例为例。将这部分患者随机划分为观察组48例(给予硫酸镁联合拉贝洛尔治疗)和对照组48例(给予硫酸镁治疗),对这两组患者的治疗效果进行对比和研究。结果经分析,观察组总有效率为95.83%,对照组总有效率为87.50%。观察组治疗效果明显优于对照组治疗效果(P<0.05);治疗前观察组收缩压以及舒张压分别为(168.72±18.23)、(96.13±5.54)mm Hg,对照组收缩压以及舒张压分别为(169.42±17.19)、(96.34±6.22)mm Hg,两组相比差异无统计学意义(P>0.05);治疗后观察组收缩压以及舒张压分别为(134.34±13.25)、(81.23±3.67)mm Hg,对照组收缩压以及舒张压分别为(149.45±12.43)、(89.45±3.55)mm Hg,观察组控制情况明显优于对照组(P<0.05);治疗后观察组患者24 h尿蛋白量为(774.7±103.2)mg,对照组为(857.8±125.4)mg,两组相比差异有统计学意义(t=3.24,P<0.05)。治疗后观察组以及对照组新生儿出生5 min后的Apgar评分分别为(9.0±0.5)分以及(8.0±1.0)分,即观察组新生儿评分明显优于对照组(t=5.66,P<0.05);治疗后观察组以及对照组剖宫产发生率分别为12.50%以及35.42%、胎盘早剥发生率分别为0.00%以及14.58%、新生儿窒息率分别为4.17%以及25.00%、胎儿窘迫率分别为8.33%以及27.08%、产后出血率分别为10.42%以及33.33%,即观察组妊娠结局明显优于对照组(P<0.05)。结论对妊娠期高血压患者行硫酸镁与拉贝洛尔联合治疗,不仅血压控制情况良好,而且能显著改善患者症状,降低尿蛋白量,提高新生儿质量,改善分娩结局,因此该种方法值得在临床上推广使用。

Objective This paper tries to investigate the clinical efficacy of magnesium sulfate combined with labetalol in the treatment of pregnancy induced hypertension.Methods 96 cases of patients with hypertension admitted in this hospital from May 2016 to May 2017 were selected as the research objects.They were randomly divided into the observation group（48 cases,given magnesium sulfate combined with labetalol treatment） and the control group（48 cases,given magnesium sulfate treatment）,the efficacy of two groups was observed and compared.Results After treatment,the total effective rate of the observation group was 95.83%.The total effective rate in the control group was 87.50%,and that of the observation group was better than the control group（P〈0.05）; Before treatment,systolic blood pressure and diastolic blood pressure in the observation group were（168.72±18.23）、（96.13±5.54） mmHg,and those in the control group were（169.42±17.19）、（96.34±6.22） mmHg,the difference was not significant（P〈0.05）; after the treatment,the systolic blood pressure and diastolic blood pressure in the observation group were（134.34±13.25） mmHg and（81.23±3.67） mmHg,and those in the control group were（149.45±12.43）、（89.45±3.55）mmHg,and those in the observation group were better than that of the control group（P〈0.05）; after treatment,the urinary protein in the observation group in 24 hours was（774.7±103.2） mg,and that in the control group was（857.8±125.4） mg,with significant difference（t=3.24,P〈0.05）; after treatment,the Apgar score of neonate after 5 minutes in observation group and the control group were（9.0±0.5） points and（8.0±1.0） points,so the observation group was significantly better than the control group（t=5.66,P〈0.05）; after treatment,the cesarean section rate,incidence rate of placental abruption,postpartum hemorrhage,neonatal asphyxia and the rate of fetal distress in the observation group and the control group were12.50% vs 35.42%; 0.00% vs 14.58%; 4.17% vs 25.00%; 8.33% vs 27.08%; 10.42% vs 33.33%,the pregnancy outcome in the observation group was significantly better than the control group（P〈0.05）.Conclusion The combined treatment of gestational hypertension patients with magnesium sulfate and labetalol not only can control the blood pressure in good condition,but also can significantly improve symptoms,reduce urinary protein,improve the quality of newborn,improve birth outcomes,so this method is worth popularization in clinical use.